CD274 and melanoma: Anti–PD-1/anti–PD-L1 antibody (anti-PD) therapy has been integrated into the standard-of-care regimens for patients with multiple types of cancers, including advanced melanoma, renal cancer, hepatocellular carcinoma, and refractory Hodgkin lymphoma (13).